Literature DB >> 20350948

Activity of drug combinations against dormant Mycobacterium tuberculosis.

Perla Filippini1, Elisabetta Iona, Giovanni Piccaro, Pascale Peyron, Olivier Neyrolles, Lanfranco Fattorini.   

Abstract

Aerobic (5-day-old cultures) and nonreplicating (dormant) Mycobacterium tuberculosis (5-, 12-, and 19-day-old cultures) bacteria were treated with rifampin (R), moxifloxacin (MX), metronidazole (MZ), amikacin (AK), or capreomycin (CP) for 7, 14, and 21 days. R-MX-MZ-AK and R-MX-MZ-CP killed both aerobic and dormant bacilli in 21 days, as shown by lack of regrowth in solid and liquid media. R-MX-MZ-AK and R-MX-MZ-CP also caused a strong decrease of nonreplicating bacilli in 7 days in a cell-based dormancy model.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20350948      PMCID： PMC2876400          DOI： 10.1128/AAC.01736-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis.

Authors:  James C Sacchettini; Eric J Rubin; Joel S Freundlich
Journal:  Nat Rev Microbiol       Date:  2008-01       Impact factor: 60.633

2.  In Vitro Model of Hypoxically Induced Nonreplicating Persistence of Mycobacterium tuberculosis.

Authors:  L G Wayne
Journal:  Methods Mol Med       Date:  2001

3.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

Review 4.  Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action.

Authors:  D I Edwards
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

5.  Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide.

Authors:  Y Hu; J A Mangan; J Dhillon; K M Sole; D A Mitchison; P D Butcher; A R Coates
Journal:  J Bacteriol       Date:  2000-11       Impact factor: 3.490

6.  A common mechanism of cellular death induced by bactericidal antibiotics.

Authors:  Michael A Kohanski; Daniel J Dwyer; Boris Hayete; Carolyn A Lawrence; James J Collins
Journal:  Cell       Date:  2007-09-07       Impact factor: 41.582

7.  Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis.

Authors:  L G Wayne; H A Sramek
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  Is adipose tissue a place for Mycobacterium tuberculosis persistence?

Authors:  Olivier Neyrolles; Rogelio Hernández-Pando; France Pietri-Rouxel; Paul Fornès; Ludovic Tailleux; Jorge Alberto Barrios Payán; Elisabeth Pivert; Yann Bordat; Diane Aguilar; Marie-Christine Prévost; Caroline Petit; Brigitte Gicquel
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

9.  Capreomycin is active against non-replicating M. tuberculosis.

Authors:  Leonid Heifets; Julie Simon; Van Pham
Journal:  Ann Clin Microbiol Antimicrob       Date:  2005-04-01       Impact factor: 3.944

Review 10.  The spectrum of latent tuberculosis: rethinking the biology and intervention strategies.

Authors:  Clifton E Barry; Helena I Boshoff; Véronique Dartois; Thomas Dick; Sabine Ehrt; JoAnne Flynn; Dirk Schnappinger; Robert J Wilkinson; Douglas Young
Journal:  Nat Rev Microbiol       Date:  2009-10-26       Impact factor: 60.633
View more
  8 in total

1.  Mycobacterium tuberculosis gene expression at different stages of hypoxia-induced dormancy and upon resuscitation.

Authors:  Elisabetta Iona; Manuela Pardini; Alessandro Mustazzolu; Giovanni Piccaro; Roberto Nisini; Lanfranco Fattorini; Federico Giannoni
Journal:  J Microbiol       Date:  2016-08-02       Impact factor: 3.422

2.  Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions.

Authors:  Giovanni Piccaro; Federico Giannoni; Perla Filippini; Alessandro Mustazzolu; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

3.  Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis.

Authors:  Nada Lelovic; Katsuhiko Mitachi; Junshu Yang; Maddie R Lemieux; Yinduo Ji; Michio Kurosu
Journal:  J Antibiot (Tokyo)       Date:  2020-05-29       Impact factor: 2.649

4.  CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis.

Authors:  Bikul Das; Suely S Kashino; Ista Pulu; Deepjyoti Kalita; Vijay Swami; Herman Yeger; Dean W Felsher; Antonio Campos-Neto
Journal:  Sci Transl Med       Date:  2013-01-30       Impact factor: 17.956

5.  Succinate dehydrogenase is the regulator of respiration in Mycobacterium tuberculosis.

Authors:  Travis Hartman; Brian Weinrick; Catherine Vilchèze; Michael Berney; Joanne Tufariello; Gregory M Cook; William R Jacobs
Journal:  PLoS Pathog       Date:  2014-11-20       Impact factor: 6.823

6.  A Flow Cytometry Method for Rapidly Assessing Mycobacterium tuberculosis Responses to Antibiotics with Different Modes of Action.

Authors:  Charlotte Louise Hendon-Dunn; Kathryn Sarah Doris; Stephen Richard Thomas; Jonathan Charles Allnutt; Alice Ann Neville Marriott; Kim Alexandra Hatch; Robert James Watson; Graham Bottley; Philip David Marsh; Stephen Charles Taylor; Joanna Bacon
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

7.  Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis.

Authors:  Diana Machado; David Pires; João Perdigão; Isabel Couto; Isabel Portugal; Marta Martins; Leonard Amaral; Elsa Anes; Miguel Viveiros
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

Review 8.  Targeting dormant bacilli to fight tuberculosis.

Authors:  Lanfranco Fattorini; Giovanni Piccaro; Alessandro Mustazzolu; Federico Giannoni
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-11-19       Impact factor: 2.576
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.